Sarepta Therapeutics, Inc. (NASDAQ:SRPT) EVP Ryan Edward Brown Sells 38,957 Shares

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) EVP Ryan Edward Brown sold 38,957 shares of the stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the completion of the transaction, the executive vice president now owns 17,129 shares of the company’s stock, valued at approximately $2,768,217.69. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Sarepta Therapeutics Stock Performance

SRPT stock opened at $158.06 on Wednesday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.44 and a current ratio of 4.05. The stock has a market cap of $14.94 billion, a P/E ratio of 1,436.91 and a beta of 0.96. The firm has a 50 day simple moving average of $127.29 and a 200 day simple moving average of $121.21. Sarepta Therapeutics, Inc. has a 52 week low of $55.25 and a 52 week high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.84. The firm had revenue of $413.50 million during the quarter, compared to analysts’ expectations of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The company’s revenue was up 63.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.44) earnings per share. Research analysts anticipate that Sarepta Therapeutics, Inc. will post 3.41 earnings per share for the current fiscal year.

Institutional Trading of Sarepta Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its stake in Sarepta Therapeutics by 37.0% in the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 87 shares during the last quarter. Vanguard Capital Wealth Advisors boosted its stake in shares of Sarepta Therapeutics by 3.8% in the 4th quarter. Vanguard Capital Wealth Advisors now owns 2,450 shares of the biotechnology company’s stock valued at $236,000 after purchasing an additional 90 shares in the last quarter. Riggs Asset Managment Co. Inc. boosted its stake in shares of Sarepta Therapeutics by 125.0% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 125 shares in the last quarter. WCM Investment Management LLC boosted its stake in shares of Sarepta Therapeutics by 2.3% in the 1st quarter. WCM Investment Management LLC now owns 6,279 shares of the biotechnology company’s stock valued at $813,000 after purchasing an additional 142 shares in the last quarter. Finally, Cary Street Partners Investment Advisory LLC boosted its stake in shares of Sarepta Therapeutics by 154.0% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 154 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently weighed in on SRPT shares. Royal Bank of Canada raised their price objective on shares of Sarepta Therapeutics from $142.00 to $182.00 and gave the company a “sector perform” rating in a research report on Friday, June 21st. BMO Capital Markets lifted their price objective on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an “outperform” rating in a research note on Monday. UBS Group lifted their price objective on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Needham & Company LLC lifted their price objective on shares of Sarepta Therapeutics from $166.00 to $235.00 and gave the stock a “buy” rating in a research note on Friday, June 21st. Finally, Bank of America raised their target price on shares of Sarepta Therapeutics from $166.00 to $213.00 and gave the stock a “buy” rating in a report on Friday, June 21st. Four analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $184.83.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.